THE CORRELATION OF MATERNAL SERUM CA-125 AND ALFA-FETOPROTEIN LEVELS WİTH FIRST TRIMESTER ABORTION

Year 2012, Volume: 9 Issue: 35, 1451 - 1455, 01.07.2012

Durdu Akarsu Hatice Işık Ali Seven Hakan Timur Gülenay Gençosmanoğlu Türkmen Sertaç Batıoğlu

Abstract

Aim: To compare maternal serum CA125 and alfa fetoprotein AFP in first trimester abortions with ongoing pregnancies to determine the clinical importance Material and Method: A prospective randomized, case-controlled clinical trial involving 116 patients at 5-12 weeks of gestation were carried out. Patients were divided into four groups Group I consisted of 34 patients with normal clinical findings; whereas Group II consisted of 32 patients with the diagnosis of threatened abortion. There were 22 patients with the diagnosis of completed/ incompleted abortion in Group III and 28 patients with the diagnosis of missed abortion in Group IV. Venous blodd samples from antecubital vein were taken from all cases. The demographic features, obstetric and gynecologic history, transvaginal ultrasonography, maternal serum CA125 and AFP levels were evaluated. Results: There was no statistically significant difference in terms of CA-125 levels between groups p=0.214 , however. median AFP levels were statistically different between groups p=0.013 . The difference was arising from higher AFP levels of Group IV. On the other hand when groups were evaluated as cases and controls, there was no statistically significant difference p=0,632 . Conclusion: Maternal serum CA-125 and AFP levels have no significant value in the prediction of abortus.

Keywords

first trimester abortion, transvaginal ultrasonography, CA-125, alfa fetoprotein

MATERNAL SERUM CA-125 VE ALFA FETO PROTEİN DÜZEYLERİNİN BİRİNCİ TRİMESTER ABORTUSLARIYLA İLİŞKİSİ

Abstract

Amaç: Maternal serum kanser antijeni CA-125 ve alfa fetoprotein AFP düzeylerini sağlıklı gebeliklerde ve birinci trimester abortuslarda karşılaştırmak ve bu farkın abortus olgularında klinik önemini saptamaktır. Gereç ve Yöntem: Prospektifrandomize, olgu kontrollü klinik çalışmaya 5-12. gebelik haftalarında 116 olgu dahil edildi ve hastalar dört gruba ayrıldı. Grup I: 34 normal seyirli gebeden, Grup II: 32 abortus imminens olgusundan, Grup III: 22 abortus kompletus/inkompletus olgusundan ve Grup IV 28 missed abortus tanısı alan hastadan oluşmakta idi. Çalışmaya dahil edilen tüm olgulardan hastaneye başvuru tarihinde antekubital venden CA125 ve AFP ölçümleri için bilgilendirilmiş onam sonrası 5 cc periferik kan örneği alındı. Tüm hastaların demografik özellikleri obstetrik ve jinekolojik öyküsü, transvaginal ultrasonografisi, maternal serum CA125 ve AFP düzeyleri değerlendirildi. Bulgular: Gruplar arasında CA-125 düzeyleri yönünden istatistiksel olarak anlamlı farklılık bulunmadı. p=0.214 AFP ortancalarıysa gruplar arasında anlamlı farklılık göstermekteydi. p=0.013 Söz konusu fark grup IV'ün AFP düzeyinin diğer gruplara göre daha yüksek olmasından kaynaklanmaktaydı, t gruplar olgu ve kontrol grubu olarak değerlendirildiğinde AFP değerleri arasında istatistiksel olarak anlamlı fark izlenmedi p=0,632 . Sonuç: Bu çalışmada maternal serum CA-125 and AFP düzeylerinin abortusu öngörmede anlamlı bir değerinin olmadığı sonucuna vardık.

Keywords

birinci trimester abortus, transvaginal ultrasonografi, Ca--25, alfa feto-protein

References

• 1. Witt BR, Wolf GC, Wanwright C, Johnson PD, Thorneycraft LH: Relaxin, CA-125, progesteron , estradiol, Schwangerschaft protein and human chorionic gonadotropin as predictors of outcome threatened and non-threatened pregnancies. Fertil Steril 1990; 53 : 1029-32
• 2. Öcer F, Beşe T, Öncül G, Aydınlı K. Abortus imminens olgularında maternal serum CA-125 ölçümünün prognostik değeri. Kadın Doğum Dergisi 1991; 87-91
• 3. Yamane Y, Takahashi K, Shibukawa T, Shirai T, Nishigaki A, Kitao M. Prognostic potential of serum C-125 levels in patients with threatened abortion. Acta Obstet Gynaecol Jpn (Eng) 1986: 38: 1781-3.
• 4. Kobayashi F. Mechanism and clinical significance of elevated CA125 levels in the sera of pregnant women. Am J Obstet Gynecol Mar 1989, 160: 563-8.
• 5. Lau HL, Linkins SE. Alfa feto protein. Am J Obstet Gynecol 1976; 124: 533-54
• 6. Speroff L, Glass RH, Kase NG, The Endocrinology of Pregnancy In Mitchell C; Clinical Gynecologic Endocrinology and Infertility 5 ed. 1994; 8. Bölüm , 251-289.
• 7. Ross HL, Elias S. Maternal serum screening for fetal genetic disorders. In Baniewics C. 24-1, Philedelphia; WB Saunders Co, 1997: 33-47.
• 8. Kaminski K, Zwirska-Korczala K, Fiegler P. Katedry i Kliniki Perinatologii Ginekologii w Zabrzu. [e-mail]
• 9. Jacops IJ, Fay TN, Stabile I, Bridges JE, Oram DH, Grudzinskas JG. The distribution of CA-125 in the reproductive tract of pregnant and nonpregnant women. Br Journal Obstet Gynecol 1988; 95 : 1190-4.
• 10. Witt BR, Miles R, Wolf GC, Koulianos GT, Torneycroft IH. CA125 levels in abruptio placentae. Am J Obstet Gynecol 1991; 164: 1225-8.
• 11. Quirk GJ, Brunson LG, Long AC. CA-125 tissues and amniotic fluid during pregnant. Am J Obstet Gynecol 1998; 159: 644-9.
• 12. O’Brien TJ, Jardin JW, Bannon GA: CA125 antigen in human amniotic fluid and fetal membranes, Am J Obstet Gynecol 1986; 155: 50-53
• 13. Barbati A, Anceschl MM; Albert P, Pomiii G, Di Renzo GC, Cosmi EV. Ontogeny of CA-125 antigen in pregnancy: immunoradiometric determination in amniotic fluid and immunohistochemical localization in fetal membranes. Am J Obstet Gynecol 1989; 160 : 513-7.
• 14. Nanbu Y, Fujii S. CA-125 in the epitelium closely related to the embryonic ectoderm: The periderm and amnion. Am J Obstet Gynecol 1989; 161: 462-7.
• 15. Atasü T. Şahmay S. Jinekoloji 2. Baskı 2001 İstanbul
• 16. Spitzer M, Kaushal N, Benjamin F. Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 1998; 43; 387-92.
• 17. Scmidt T, Rein DT, Foth D, Eibach HW, Kurbacher CM, Mallmann P, et al. Prognostic value of repeated serum CA125 measurements in first trimester pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 97; 168-173
• 18. Yamane Y, Takahashi K, Yoshino K, et al. Prognostic potential of serum CA-125 levels in patients with threatened abortion. Nippon Sanka Fujinka Gakkai Zasshi 1986; 38: 1781-2.
• 19. Hornstein MD, Check JH, Hill JA. Serum CA-125 levels and spontaneous abortion. Am J Obstet Gynecol 1995; 172; 695-9.
• 20. Check HJ, MD, Mowrozik, MD. Serum CA-125 levels in early pregnancy and subsequent spontaneous abortion. Obstet Gynecol 1990; 75 ; 742.
• 21. C.F. Dalton, S.M.Laird, S.E.Estdale, H.G. Saravelos and T.C. Li; Human Reproduction 1998;13; 3197-3202
• 22. Katz VL, Chescheir NC, Cefalo RC. Unexplained elevations of maternal serum alpha fetoprotein. Obstet and Gynecol Survey 1990; 45 ; 719-26
• 23. Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, Desilets VA, Johnson JA, Langlois S, Summers A, Wyatt P; Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Vancouver BC.
• 24. Salvatore A, Emanuele S, Patrizia B, Giovanni P, Dandolo G; Acta Biomed 2007; 78: 214-219
• 25. Stabile I, Olajide F, Chard T, Grudzinskas JG. Joint Academic Unit of Obstetrics and Gynaecology and Reproductive Physiology, Medical College, London Hospital , UK.
• 26. Hay DM, Forrester PI, Lai PC, Lorscheider FL. Maternal serum alpha-fetoprotein in abnormal pregnancies and during induced abortion. J Reprod Med. 1977 ; 19 (2); 75-78